{
    "title": "French drug developer Pharnext to take rare approach to pricing",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-3361377/French-drug-developer-Pharnext-rare-approach-pricing.html",
    "date": "2015-12-15",
    "keywords": [
        "drug",
        "cmt",
        "development",
        "developer",
        "approach",
        "pricing",
        "gmt",
        "december",
        "treatment",
        "disorder",
        "percent",
        "cost",
        "patient",
        "cohen",
        "form",
        "disease",
        "pharnext",
        "email",
        "groverdec",
        "sas",
        "latestage",
        "trial",
        "charcotmarietooth",
        "profit",
        "yettobe",
        "drugsmany",
        "year",
        "marketdrug",
        "issue",
        "backlash",
        "gilead",
        "fire",
        "diseasesdrug",
        "innovation",
        "risk",
        "combination",
        "chief",
        "executive",
        "daniel",
        "market",
        "europe",
        "statesthe",
        "overexpression",
        "gene",
        "muscle",
        "atrophy",
        "care",
        "therapy",
        "surgeryabout",
        "wheelchairgood",
        "rewardcohen",
        "mapping",
        "genome",
        "pxt3003but",
        "mistake",
        "research",
        "rewardoutside",
        "volume",
        "strategy",
        "safety",
        "costscohen",
        "price",
        "pxt3003",
        "baclofen",
        "naltrexone",
        "sorbitol",
        "agreement",
        "health",
        "insurersit",
        "range",
        "return",
        "investment",
        "way",
        "money",
        "reporting",
        "grover",
        "bengaluru",
        "editing",
        "kalluvila"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}